Loic Maurel, Md Email and Phone Number
Loic Maurel, Md work email
- Valid
Loic Maurel, Md personal email
- Valid
Loic Maurel, Md phone numbers
30 years of senior management experience in tier-one pharmaceutical companies and Biotech.As the CEO of the Diaxonhit Group (now Eurobio Scientific), Loïc inspired and led the transformation of Exonhit Therapeutics, a pure biotech company, into a full fledge commercial IVD company following the acquisition of Ingen BioSciences and Eurobio with sales over 50M€. Eurobio Scientific is listed on Euronext Paris (ticker: ALERS, previously ALEHT, since 2005). Previously, as the CEO of Debiovision Inc., during 8 years, a Canadian Biotech company, Loïc acquired clinical & regulatory experience with FDA & EMEA exposure, filing of NDA at the FDA and other countries in the World. Loïc negociated multiple licencing deals with companies such as Salix Inc., LG, Ranbaxy, AstraZeneca / Cambridge Antibody Technology, Oncomab, EMS Sigma PharmaHe was previously VP, Marketing & Specialty Business at Novartis Canada (1999 - 2000) after moving from Basel, Switzerland (1992 - 1998) where he headed Global Marketing for CVS/Metabolism & Respiratory Therapeutic Division at Novartis Headquarters. Loïc launched several drugs, including the worldwide launch of formerly Novartis top-seller, Diovan. Dr. Maurel was previously Chairman of the Board of OncoMab™ GmbH, Board member of Avance Pharma and of the BioQuebec association, vice president of France Biotech, president of the IVD Medicen DAS (Paris Region Dx cluster), member of the Health Expert Committee of M Capital Partners, a French leading fund, director of Trans Hit Biomarkers, of the Global Advisory Board of Debiopharm in Switzerland, and Luxia Scientific.Loïc is a Board member VIMS and Gour Medical, and Chairman of the Board of Diafir.
-
PresidentLisco-Health 2017 - PresentLiSCo Health is a Consulting boutique integrating Market access, Commercial, M&A and Financing capabilities
-
Chairman Of The BoardDiafir Jul 2021 - PresentRennes, Bretagne, Fr
-
Board Member VimsVims System Nov 2021 - Apr 2024Villeneuve-Lès-Bouloc, FrGood news - Zimmer Biomet acquires Vims -
Board MemberGour Medical Nov 2018 - Apr 2022
-
AdministrateurTrans-Hit Biomarkers, Inc. Feb 2018 - Dec 2020Trans-Hit Bio is the worldwide biospecimen access CRO with the most extensive collection capability for biospecimens and clinical samples through an unrivaled worldwide partnered-network state-of-the-art academic biorepositories and clinical sites.
-
Member Of The Health Expert CommitteeM Capital Partners 2014 - 2019Toulouse, FrM Capital Partners is a rapidly growing independent private equity company, specialized in financing small and medium businesses. M Capital Partners manages over €380 million and a portfolio of investments of 170 small and medium companies covering a wide range of industrial and service sectors. These portfolio companies employ over 9,500 people and generated revenues of over €1,6 billion altogether in 2016, 21% above their 2015 level. In 2012 and 2013, M Capital Partners was nominated as one of the 3 best French companies for capital venture by Capital Finance / Les Echos. In 2014, 2015 and 2016, M Capital Partners is in the TOP 3 favorite asset managers among French independent investment advisors according to the “Gestion de Fortune” ranking. -
Member Of The Diagnostics Advisory BoardDebiopharm International Sa 2015 - 2018Lausanne, ChDebiopharm Group™ is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management.For more information, please see www.debiopharm.com We are on Twitter. Follow @DebiopharmNews at http://twitter.com/DebiopharmNews -
Ceo & President Of The Management BoardDiaxonhit Jul 2008 - Jun 2017Paris, FrDiaxonhit Group (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in the in vitro diagnostic field, involved from research to commercialization of specialty diagnostic products.After the acquisition of Ingen in December 2012, Diaxonhit announced the acquisition of Eurobio in January 2017, implementing its announced build up strategy.• The new group reaches a critical mass, with €44 million in pro forma revenue in 2015.• An innovative, integrated company, positioned in the fastest growing market segments, including molecular biology.• A strong presence in complementary markets, in vitro diagnostics, life sciences research and corneal transplantation.• One of the largest sales forces in France.• Significant growth drivers, including an expanded portfolio of proprietary products and a strong international development.• Immediate synergies aimed at achieving a positive restated EBITDA by Q4 2017.Diaxonhit is the Worldwide lead distributor of HLA products from Life Tech / Thermo Fisher / One Lambda and the #1 European distributor of Quidel.The group also owns a diversified portfolio of proprietary products in development, covering infection diseases, cancer, corneal transplantation and Life Sciences Research.The Group is a member of the European GIE – DiaMondial.The Group is part of the Alternext BPI Innovation, PEA – PME 150 and Next Biotech.Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index.For more information, please visit: www.diaxonhit.com -
Ceo & President Of The Management BoardDiaxonhit Jul 2008 - Dec 2012Paris, FrExonhit changed its name into Diaxonhit after the acquisition of Ingen Biosciences in 2012.See full description in Diaxonhit.
-
Vice President France Biotech & Président Of The Diagnostic And Medtech Commission.France Biotech Jul 2008 - 2016Paris, Île-De-France, FrCréée en 1997, France Biotech est l’institution française qui regroupe les principales entreprises des sciences dela vie et ses partenaires experts. France Biotech a pour mission d’accompagner le développement de cetteindustrie en France sur un terrain législatif et fiscal favorable. A l’origine du statut de Jeune Entreprise Innovante(JEI) mis en place lors de la Loi de Finances de 2004, France Biotech milite pour que le secteur innovant représente une industrie performante à part entière. France Biotech est présidée par Maryvonne Hiance et compte plus de 150 membres et un conseil d’administration issu de représentants de 20 entreprises innovantes du secteur de la santé. -
President And CeoDebiovision (Formerly H3 Pharma) Jul 2001 - Jun 2008Ca• Successfully built a Pharmaceutical Development Company on an innovative business model• Recruited an experienced R&D, Manufacturing, F&A, Legal, BD&L team evaluating over 600 technologies• Licensed-in a solid early (monoclonal antibodies) and late phase portfolio (vapreotide IR and SR formulations)• Acquired a German Biotech start-up specialized in human monoclonal antibodies and cancer• Negotiated and signed several out licensing deals e.g. CAT / Astra Zeneca, Salix, LG, Ranbaxy• Achieved critical R&D milestones including 1 MAA, US & EU NDA filing, orphan drug designations, US INDs, phase 2 clinical trials in Hepatitis C and Alzheimer in Canada and phase 3 in Portal Hypertension in USA -
President And CeoH3 Pharma Inc. 2001 - 2005CaFollowing the acquisition of H3 Pharma in March 2005 by the Debio's Group in Lausanne, the company's name is now Debiovision. -
Vice President Marketing And Specialty BusinessNovartis Pharmaceuticals Canada 1999 - 2001Basel, Baselstadt, Ch• A sales budget responsibility of CAD $ 327 Mio.• Scope of responsibility included: product management, GPs and specialty business sales forces, trade relations / customer service & distribution, generics, e-business, market research, scientific relations & convention services.• Reengineered marketing & sales organization (235 associates) resulting in a 1999 sales growth of 9.5% after 3 years without growth. Launched successfully several brands including Sandostatin (octreotide) LAR, Diovan HCT, Miacalcin Nasal Spray• Managed one downsizing (30 associates) and two re-organizations.• As a member of the Canadian Novartis Executive Committee contributed in setting overall country organization policy and direction, and strategic planning development processes.• Following a worldwide business unit re-organization, nominated VP Marketing & Sales Neuroscience in 2001. -
Global Marketing Head Of Cardiovasculars / Metabolism And RespiratoryNovartis 1996 - 1998Basel, Baselstadt, Ch• Led the largest Novartis therapeutic franchise, supervising three global marketing groups.• Spearheaded strategic reassessment of the CMR portfolio to focus on greatest growth opportunities, which included key brands in hypertension (Diovan), hypercholesterolemia, diabetes, asthma and COPD.• Established Diovan as major growth driver and future No. 1 product of Novartis Pharmaceuticals • Developed global vision and strategic direction that has resulted in the fastest growing brands within Novartis. Grew sales by SF 500 Mio during the first year and achieved SF 3 Bio in total sales.
-
Global Marketing Head Of CardiovascularsNovartis 1995 - 1996Basel, Baselstadt, Ch• Supervised a team of International Marketing Managers in growing Ciba-Geigy’s CVS franchise to SF 1 400 Mio.• Served as the International marketing representative on the global cardiovascular Therapeutic Area Review Board.• Led the Global Diovan Launch Team and created vision and strategic plans to successfully launch Diovan the No. 1 company’s priority product.
-
Global Cardiovasculars Product ManagerNovartis (Formerly Ciba Geigy) Pharmaceuticals Headquarters 1992 - 1994• Developed and implemented strategic vision for Lotensin franchise resulted in global sales of over SF 1 Bio.• Provided guidance to international project team to ensure market driven life cycle management.• Served as global marketing representative on the newly formed Global Thrombosis Strategic Team.
-
Cardiovasculars Product ManagerNovartis (Formerly Ciba Geigy) France 1989 - 1992• Developed and implemented strategic vision for Lotensin franchise resulted in global sales of over SF 1 Bio.• Provided guidance to international project team to ensure market driven life cycle management.• Served as global marketing representative on the newly formed Global Thrombosis Strategic Team.
-
Regional Medico Marketing ManagerSanofi (Formerly Rhone Poulenc Theraplix) France 1987 - 1989• Promoted to regional medico-marketing manager supporting three district managers and a total of 65 representatives. Developed the regional medico-marketing strategy for the launch of two major brands.• Responsibilities expanded to include training, recruiting, as well as providing business analyses and strategic direction to representatives, which positively impacted regional sales.
-
Sales RepresentativeSanofi (Formerly Rhone Poulenc Specia) France 1985 - 1987• Promoted cardiovascular and neuroscience brands to physicians, pharmacists and hospital administrators. Conducted educational programs for hospital and residents.• Significantly increased sales in the territory.
-
Chairman Of The BoardSociété Mutualiste Des Etudiants Du Sud-Ouest 1976 - 1984• Managed the student insurance company and expanded membership by more than 15 times to reach 65,000 members, achieving annual sales of Euros 8 Mio. Promoted to Board member in 1979 and Chairman of the Board in 1982.
Loic Maurel, Md Skills
Loic Maurel, Md Education Details
-
Université De BordeauxMedecine -
Ecole Grand Lebrun Bordeaux, FranceSciences Physiques
Frequently Asked Questions about Loic Maurel, Md
What company does Loic Maurel, Md work for?
Loic Maurel, Md works for Diafir
What is Loic Maurel, Md's role at the current company?
Loic Maurel, Md's current role is Chairman of the Board of Diafir - Member of the French Tech Bordeaux.
What is Loic Maurel, Md's email address?
Loic Maurel, Md's email address is lo****@****hit.com
What is Loic Maurel, Md's direct phone number?
Loic Maurel, Md's direct phone number is (240)-683*****
What schools did Loic Maurel, Md attend?
Loic Maurel, Md attended Université De Bordeaux, Ecole Grand Lebrun Bordeaux, France.
What skills is Loic Maurel, Md known for?
Loic Maurel, Md has skills like Pharmaceutical Industry, Biotechnology, Oncology, Clinical Trials, Regulatory Affairs, Cancer, Strategy, Lifesciences, R&d, Commercialization, Infectious Diseases, Clinical Development.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial